Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
European Journal of Medicinal Chemistry|May 6, 2014
Synthesis and structure-activity relationship of trisubstituted thiazoles as Cdc7 kinase inhibitorsAndreas Reichelt, Julie M Bailis, Michael D Bartberger, et al.
Bioorganic & Medicinal Chemistry Letters|March 14, 2013
N-substituted azaindoles as potent inhibitors of Cdc7 kinaseMarian C Bryan, James R Falsey, Mike Frohn, et al.
Journal of Hematology & Oncology|June 24, 2023
Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancerCharles M Rudin, Martin Reck, Melissa L Johnson, et al.
Molecular Cancer Therapeutics|August 11, 2021
Preclinical Assessment of a MUC12-Targeted BiTE (Bispecific T-cell Engager) MoleculeElizabeth Pham, Matthias Friedrich, Famke Aeffner, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 1, 2021
Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissuesFrans V Suurs, Grit Lorenczewski, Julie M Bailis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 28, 2021
The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate CancerPetra Deegen, Oliver Thomas, Olivier Nolan-Stevaux, et al.
Cancer Research|April 9, 2026
Nonsense-Mediated RNA Decay is a Targetable Vulnerability in Splicing Factor Mutant Myeloid Neoplasms by Enhancing R-loop Accumulation and DNA DamageClaudia Cabrera Pastrana, Sridhar Nonavinkere Srivatsan, Michael O Alberti, et al.
Bioorganic & Medicinal Chemistry Letters|October 15, 2013
The optimization of aminooxadiazoles as orally active inhibitors of Cdc7Paul E Harrington, Matthew P Bourbeau, Christopher Fotsch, et al.
Cancer Research|July 3, 2021
Nonsense-Mediated RNA Decay Is a Unique Vulnerability of Cancer Cells Harboring <i>SF3B1</i> or <i>U2AF1</i> MutationsAbigael Cheruiyot, Shan Li, Sridhar Nonavinkere Srivatsan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2020
AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung CancerMichael J Giffin, Keegan Cooke, Edward K Lobenhofer, et al.
Pageof 4